Denali Therapeutics Inc.

Historical 13F Holders

Symbol
DNLI
CUSIP
24823R105
All holders as of
Q2 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 24823R105 since 12/18/2024, largest first.

Filer % of Class Filed
T. Rowe Price Investment Management, Inc. 13G/A 10.2% 7/8/2026
Event 6/30/2026
Baillie Gifford & Co 13G/A 7.5% 8/4/2026
Event 6/30/2026
BlackRock, Inc. 13G/A 7.2% 4/17/2025
Event 3/31/2025
Under 5%, checked the "5 percent or less" box, or amended by a later filing (4)
FMR LLC 13G/A
4.2% 5/6/2026
Event 3/31/2026
Wellington Management Group LLP 13G/A
3.9% 8/12/2025
Event 6/30/2025
Capital Research Global Investors 13G/A 3.8% 2/13/2025
Event 12/31/2024
Vanguard Group Inc 13G/A 0% 3/26/2026
Event 3/13/2026

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 5 19.9 k $411 k
2026 Q2 305 160 M $4.61 B
2026 Q1 286 148 M $2.83 B
2025 Q4 259 152 M $2.52 B
2025 Q3 250 136 M $1.97 B
2025 Q2 242 138 M $1.93 B
2025 Q1 230 136 M $1.85 B
2024 Q4 234 128 M $2.61 B
2024 Q3 229 127 M $3.70 B
2024 Q2 220 126 M $2.92 B
2024 Q1 226 124 M $2.55 B
2023 Q4 230 117 M $2.51 B
2023 Q3 209 109 M $2.24 B
2023 Q2 214 108 M $3.18 B
2023 Q1 214 108 M $2.49 B
2022 Q4 212 111 M $3.08 B
2022 Q3 213 92.9 M $2.85 B
2022 Q2 197 92.9 M $2.74 B
2022 Q1 199 87.1 M $2.81 B
2021 Q4 228 85.5 M $3.81 B
2021 Q3 224 84.8 M $4.28 B
2021 Q2 223 80.8 M $6.33 B
2021 Q1 230 80.5 M $4.60 B
2020 Q4 225 89.1 M $6.17 B
2020 Q3 181 82.8 M $2.97 B
2020 Q2 155 83.0 M $2.01 B
2020 Q1 137 80.7 M $1.41 B
2019 Q4 114 71.7 M $1.25 B
2019 Q3 126 72.7 M $1.12 B
2019 Q2 125 71.6 M $1.49 B
2019 Q1 118 69.1 M $1.60 B
2018 Q4 93 68.8 M $1.42 B
2018 Q3 82 67.2 M $1.46 B
2018 Q2 69 62.2 M $949 M
2018 Q1 59 61.1 M $1.20 B
2017 Q4 45 58.1 M $909 M